Treatment selection in metastatic renal cell carcinoma: expert consensus

@article{Escudier2012TreatmentSI,
  title={Treatment selection in metastatic renal cell carcinoma: expert consensus},
  author={Bernard Escudier and Cezary A. Szczylik and Camillo Porta and Martin Gore},
  journal={Nature Reviews Clinical Oncology},
  year={2012},
  volume={9},
  pages={327-337}
}
In metastatic renal cell carcinoma (mRCC), many factors influence clinical decisions, including histology, tumour burden, prognostic factors, comorbidities, and the ability of the patient to tolerate treatment. Progression-free survival (PFS) durations reported from randomized trials of targeted therapies vary considerably, in part because of differences in patient characteristics. For first-line therapy, an estimate of PFS with sunitinib, bevacizumab plus interferon, or sorafenib in a 'general… CONTINUE READING